Skip to main content

Advertisement

SpringerLink
Log in

Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis

  • Practice Point
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Talar-Williams C et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124: 477–484

    Article  CAS  Google Scholar 

  2. Knight A et al. (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63: 1307–1311

    Article  CAS  Google Scholar 

  3. De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469

    Article  CAS  Google Scholar 

  4. Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    Article  CAS  Google Scholar 

  5. Jayne D et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36–44

    Article  CAS  Google Scholar 

  6. Langford CA et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114: 463–469

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Rheumatic and Immunologic Diseases, ES Molloy is a staff member and CA Langford is the Director at the Center for Vasculitis Care and Research, Cleveland Clinic, OH, USA.,

    Eamonn S Molloy & Carol A Langford

Authors
  1. Eamonn S Molloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A Langford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol A Langford.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molloy, E., Langford, C. Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis. Nat Rev Rheumatol 4, 340–341 (2008). https://doi.org/10.1038/ncprheum0822

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0822

  • Springer Nature Limited

Search

Navigation